
Annual report 2022
added 09-29-2022
Opthea Limited Net Debt 2011-2026 | OPT
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt Opthea Limited
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | -21.5 M | -32.5 M | -52 M | -14.5 M | -18.4 M | -7.16 M | -11 M | -16.4 M | -22.1 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -7.16 M | -52 M | -21.7 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Biotechnology industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
163 M | - | 2.43 % | $ 254 M | ||
|
AgeX Therapeutics
AGE
|
12.6 M | - | -10.17 % | $ 12.2 K | ||
|
I-Mab
IMAB
|
-1.06 B | - | - | $ 866 M | ||
|
Esperion Therapeutics
ESPR
|
-165 M | $ 3.13 | 0.55 % | $ 651 M | ||
|
Exelixis
EXEL
|
-282 M | $ 48.2 | 8.51 % | $ 13.1 B | ||
|
Midatech Pharma plc
MTP
|
-6.17 M | - | -18.52 % | $ 27.3 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
-402 M | - | - | $ 40.3 B | ||
|
Fortress Biotech
FBIO
|
-24.8 M | $ 2.53 | 2.85 % | $ 70.6 M | ||
|
Biophytis SA
BPTS
|
-4.01 M | - | -13.47 % | $ 169 M | ||
|
Genfit SA
GNFT
|
2.27 M | - | 2.54 % | $ 160 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
-824 K | - | -1.52 % | $ 24.7 M | ||
|
Galapagos NV
GLPG
|
-1.29 B | $ 28.81 | 1.48 % | $ 2.69 B | ||
|
Athira Pharma
ATHA
|
-68.5 M | - | - | $ 269 M | ||
|
Genmab A/S
GMAB
|
-6.94 B | $ 27.95 | 1.5 % | $ 17.2 B | ||
|
Genprex
GNPX
|
-27.3 M | $ 0.91 | 2.24 % | $ 849 K | ||
|
Grifols, S.A.
GRFS
|
5.36 B | $ 8.4 | 1.63 % | $ 6.83 B | ||
|
InflaRx N.V.
IFRX
|
-32.3 M | $ 2.51 | 27.16 % | $ 152 M | ||
|
Ionis Pharmaceuticals
IONS
|
965 M | $ 77.0 | 2.33 % | $ 12.3 B | ||
|
BioNTech SE
BNTX
|
-973 M | $ 94.64 | -0.9 % | $ 27.2 B | ||
|
Kamada Ltd.
KMDA
|
-70.2 M | $ 8.29 | 0.91 % | $ 260 M | ||
|
Институт стволовых клеток человека
ISKJ
|
246 M | - | - | - | ||
|
Checkmate Pharmaceuticals
CMPI
|
-12.1 M | - | - | $ 231 M | ||
|
Kymera Therapeutics
KYMR
|
-344 M | $ 85.79 | 3.72 % | $ 7.25 B | ||
|
Kazia Therapeutics Limited
KZIA
|
-5.43 M | $ 13.58 | 0.97 % | $ 1.8 B | ||
|
Ligand Pharmaceuticals Incorporated
LGND
|
-71 M | $ 231.58 | -0.31 % | $ 4.24 B | ||
|
INmune Bio
INMB
|
-23.7 M | $ 1.54 | - | $ 38.1 M | ||
|
Liquidia Corporation
LQDA
|
-72.5 M | $ 41.64 | 3.75 % | $ 3.58 B | ||
|
ACADIA Pharmaceuticals
ACAD
|
-83 M | $ 22.58 | 1.03 % | $ 3.74 B | ||
|
Mirum Pharmaceuticals
MIRM
|
-287 M | $ 107.36 | 1.46 % | $ 5.39 B | ||
|
MannKind Corporation
MNKD
|
282 M | $ 3.61 | 26.17 % | $ 1.1 B | ||
|
Advaxis
ADXS
|
3.42 M | - | -9.65 % | $ 45.9 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
-3.5 M | $ 3.46 | -1.14 % | $ 5.7 M | ||
|
Aeterna Zentaris
AEZS
|
-65.1 M | - | 5.93 % | $ 314 M | ||
|
Aeglea BioTherapeutics
AGLE
|
-30.2 M | - | - | $ 1.01 B | ||
|
CureVac N.V.
CVAC
|
-783 M | - | - | $ 867 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
-36 M | - | - | $ 26.5 M | ||
|
AIkido Pharma
AIKI
|
-31.2 M | - | 1.93 % | $ 17.4 M | ||
|
Akero Therapeutics
AKRO
|
-340 M | - | - | $ 3.67 B | ||
|
Aptose Biosciences
APTO
|
-5.53 M | - | -45.71 % | $ 1.2 M | ||
|
Aptinyx
APTX
|
-33.8 M | - | -39.0 % | $ 4.57 M | ||
|
Akouos
AKUS
|
-92.9 M | - | 0.23 % | $ 488 M | ||
|
Albireo Pharma
ALBO
|
-239 M | - | -0.23 % | $ 916 M | ||
|
Allakos
ALLK
|
-25 M | - | - | $ 28.6 M | ||
|
AlloVir
ALVR
|
-62.7 M | - | 4.14 % | $ 49.1 M | ||
|
Arcutis Biotherapeutics
ARQT
|
65.3 M | $ 24.0 | 2.46 % | $ 3.05 B | ||
|
Nanobiotix S.A.
NBTX
|
-80 M | $ 41.6 | 19.64 % | $ 286 B | ||
|
Allena Pharmaceuticals
ALNA
|
-29.5 M | - | 3.16 % | $ 1.9 M | ||
|
Ampio Pharmaceuticals
AMPE
|
-12 M | - | -11.43 % | $ 502 K | ||
|
Applied Molecular Transport
AMTI
|
-56.5 M | - | - | $ 10.1 M | ||
|
Alpine Immune Sciences
ALPN
|
-63.9 M | - | - | $ 2.17 B |